(Reuters) - A Pennsylvania federal judge on Tuesday curbed the reach of an antitrust case that dozens of states brought against generic drugmakers, ruling that New York, California, Connecticut and ...

Hikma and the U.S. government cautioned that a ruling for Amarin could deter generic competition. The report also noted that Vascepa, derived from fish oil, has been approved by the Food and Drug ...

Drugmaker Hikma's generic version of Amarin Pharma's cardiovascular medication Vascepa did ⁠not ⁠infringe Amarin's patents, the U.S. Supreme Court ruled on Thursday ⁠in a decision that may make ...

In a massive case, in which states are suing makers of generic drugs over an alleged price-fixing scheme, score one for the states and one for the drugmakers. On Tuesday, a federal district court ...

On June 4 2019, the Japan Fair Trade Commission (JFTC) issued a cease and desist order and surcharge payment order to KOA ISEI Co LTD (KOA ISEI) under the provisions of the Antimonopoly Act. In this ...

States Battle Malpractice Cases: Some Good News, Some Not Defendants Could Be Charged With 2 Deaths "Bizarre Outcome" Makes it Tougher to Sue Manufacturers of Generic Drugs Medicare Advantage: A Real ...

The Supreme Court on Jan. 16, 2026, agreed to decide a case about how generic companies can communicate to the market about their products, including whether their product promotion may infringe ...

Attorneys general from 46 states and the District of Columbia expanded their antitrust case against the $75 billion generic drug industry to include 18 companies and at least 15 drugs. HARTFORD, Conn.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...